Use of gastrointestinal prokinetics and the risk of parkinsonism: A population-based case-crossover study

被引:0
|
作者
Kim, Eunji [1 ,2 ]
Kim, Siin [3 ,4 ]
Suh, Hae Sun [3 ,4 ,5 ,6 ]
机构
[1] Pusan Natl Univ, Dept Pharm, Yangsan Hosp, Yangsan, South Korea
[2] Pusan Natl Univ, Res Inst Convergence Biomed Sci & Technol, Yangsan Hosp, Yangsan, South Korea
[3] Kyung Hee Univ, Coll Pharm, Seoul, South Korea
[4] Kyung Hee Univ, Inst Regulatory Innovat Sci IRIS, Seoul, South Korea
[5] Kyung Hee Univ, Grad Sch, Dept Regulatory Sci, Seoul, South Korea
[6] 26 Kyungheedae Ro, Seoul 02447, South Korea
基金
新加坡国家研究基金会;
关键词
case-crossover study; drug related side effects and adverse reactions; gastrointestinal agents; insurance claims analyses; parkinsonism disorders; DRUG-INDUCED PARKINSONISM; ANTIPSYCHOTICS; LEVOSULPIRIDE; DISEASE; STROKE;
D O I
10.1002/pds.5668
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: The disease burden of parkinsonism is extremely costly in the United States. Unlike Parkinson's disease, drug-induced parkinsonism (DIP) is acute and reversible; exploring the causative drug is important to prevent DIP in patients at high-risk of parkinsonism. Objective: To examine whether the use of gastrointestinal (GI) prokinetics is associated with an increased risk of parkinsonism. Methods: We conducted a case-crossover study using nationally representative data. We included patients who were newly diagnosed with parkinsonism (ICD-10 G20, G21.1, G25.1) between January 1, 2007 and December 1, 2015. The first prescription date of G20, G21.1, or G25.1 diagnoses was defined as the index date (0 day). Patients with prior extrapyramidal and movement disorders or brain tumors were excluded. We assessed the exposure within the risk (0-29 days) and control periods (60-89 days), before or on the index date. Conditional logistic regression estimated the adjusted odds ratio (aOR) for parkinsonism. Results: Overall, 2268 and 1674 patients were exposed to GI prokinetics during the risk and control periods, respectively. The use of GI prokinetics significantly increased the occurrence of parkinsonism (aOR = 2.31; 95% Confidence Interval [CI], 2.06-2.59). The use of GI prokinetics was associated with a higher occurrence of parkinsonism in elderly patients (>= 65 years old; aOR = 2.69; 95% CI, 2.30-3.14) than in younger patients (aOR = 1.90; 95% CI, 1.59-2.27). Conclusions: The use of GI prokinetics was significantly associated with higher occurrences of parkinsonism, necessitating close consideration when using GI prokinetics. Key Points circle The burden of Parkinson's disease has increased with the growth of the elderly population. circle While Parkinson's disease is a neurodegenerative disease, drug-induced parkinsonism is acute and reversible after withdrawal of drugs associated with parkinsonism. circle We conducted a population-based case-crossover study to examine the association between the use of gastrointestinal prokinetics and the occurrence of parkinsonism.
引用
收藏
页码:1378 / 1386
页数:9
相关论文
共 50 条
  • [41] Generic substitution of antiepileptic drugs and loss of seizure control: a population-based case-crossover study
    Polard, E.
    Nowak, E.
    Happe, A.
    Biraben, A.
    Oger, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2014, 28 : 29 - 29
  • [42] Maternal Depression and Antidepressant Use During Pregnancy and Risk of Autism Spectrum Disorders in Offspring: Population-based Cohort and Bidirectional Case-Crossover Sibling Study
    Hagberg, Katrina Wilcox
    Robijn, Annelies
    Jick, Susan S.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 470 - 470
  • [43] Comment on: Risk of neuropsychiatric adverse events associated with the use of oseltamivir: a nationwide population- based case-crossover study
    Ohkusa, Yasushi
    Sugawara, Tamie
    Taniguchi, Kiyosu
    Miyazaki, Chiaki
    Momoi, Mariko Y.
    Okabe, Nobuhiko
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (06) : 1762 - 1764
  • [44] Syncope and Traf i c Crash: A Population-Based Case-Crossover Analysis
    Staples, John A.
    Erdelyi, Shannon
    Merchant, Ketki
    Yip, Candace
    Khan, Mayesha
    Maclure, K. Malcolm
    Redelmeier, Donald A.
    Chan, Herbert
    Brubacher, Jeffrey R.
    CANADIAN JOURNAL OF CARDIOLOGY, 2024, 40 (04) : 554 - 561
  • [45] Decongestant use and the risk of myocardial infarction and stroke: a case-crossover study
    Grimaldi-Bensouda, Lamiae
    Begaud, Bernard
    Benichou, Jacques
    Nordon, Clementine
    Dialla, Olivia
    Morisot, Nicolas
    Hamon, Yann
    Cottin, Yves
    Serrano, Elie
    Abenhaim, Lucien
    Touze, Emmanuel
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [46] Risk of Cardiovascular Adverse Events and Domperidone Use: A Case-Crossover Study
    Shin, Sun Mi
    Li, Junqing
    Kim, Hye-Jun
    Lee, Hyesung
    Shin, Ju-Young
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 49 - 49
  • [47] Medicine Use and the Risk of Hip Fracture in the Elderly: A Case-Crossover Study
    Leach, Michael J.
    Pratt, Nicole L.
    Roughead, Elizabeth E.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 180 - 181
  • [48] Polyethylene Glycol Increase Risk of Acute Renal Failure: A Population Based Case-Crossover Study
    Choi, Nam-Kyong
    Lee, Joongyub
    Chang, Yoosoo
    Jung, Sun-Young
    Kim, Ye-Jee
    Lee, Seung-Mi
    Lee, Jin-Ho
    Kim, Ju-Young
    Park, Byung-Joo
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S256 - S257
  • [49] Decongestant use and the risk of myocardial infarction and stroke: a case-crossover study
    Lamiae Grimaldi-Bensouda
    Bernard Begaud
    Jacques Benichou
    Clementine Nordon
    Olivia Dialla
    Nicolas Morisot
    Yann Hamon
    Yves Cottin
    Elie Serrano
    Lucien Abenhaim
    Emmanuel Touzé
    Scientific Reports, 11
  • [50] New use of benzodiazepines and the risk of hip fracture: A case-crossover study
    Hoffmann, F
    Glaeske, G
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2006, 39 (02): : 143 - 148